Share

Enveric Biosciences Inc. - news published 259 - readings 4.313

BACK
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Letter of Marcum LLP to the Securities and Exchange Commission, dated June 25, 2021 (Form 8-K)

Exhibit 16.1 June 25, 2021 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Ladies and Gentlemen: We have read the statements made by Enveric Biosciences, Inc. under Item 4.01 of its Form 8-K filed on June 25, 2021. We agree with the statements concerning our Firm under Item 4.01; we are not in a position to agree or d ...

Continue reading
28.06.2021
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Registration of Securities issued in Business Combination Transaction (SEC Filing - S-4)

Exhibit 99.1 Consent of Gemini Valuation Services, LLC Gemini Valuation Services, LLC ('Gemini') hereby consents to (i) the inclusion of our opinion letter dated May 21, 2021 (the 'Opinion') to the Board of Directors of Enveric Biosciences, Inc. as Annex D to the proxy statement/prospectus that is being filed on or promptly after the date hereof with the Securities and Exchang ...

Continue reading
22.06.2021
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Announces Definitive Agreement to Acquire MagicMed Industries, a Pharmaceutical Drug Discovery and Development Platform Focused on New-Generation Psychedelic Molecular Compounds and Derivatives

Enveric Biosciences Announces Definitive Agreement to Acquire MagicMed Industries, a Pharmaceutical Drug Discovery and Development Platform Focused on New-Generation Psychedelic Molecular Compounds and Derivatives May 24, 2021 With this acquisition, Enveric will expand and complement its pipeline of naturally occurring cannabinoid compounds with a robust portfolio of psychedel ...

Continue reading
24.05.2021